| Item |
Medicine |
| Brand name |
Viekirax |
| Generic name |
Ombitasvir, Paritaprevir and Ritonavir |
| Final report date |
03/27/2019 |
|
|
| Target population (1) |
Chronic hepatitis C GT1 (Y93/L31 wildtype) |
| Comparator |
Daclatasvir/Asunaprevir |
| ICER |
JPY 7.5 million/QALY and over, less than JPY 10 million/QALY |
|
|
| Target population (2) |
Chronic hepatitis C GT1(Y93 wildtype and L31 mutant) |
| Comparator |
Only follow-up (no treatment) |
| ICER |
Dominant |
|
|
| Target population (3) |
Compensated cirrhosis C GT1(Y93/L31 wildtype) |
| Comparator |
Daclatasvir/Asunaprevir |
| ICER |
JPY 10 million/QALY and over |
|
|
| Target population (4) |
Compensated cirrhosis C GT1(Y93 wildtype and L31 mutant) |
| Comparator |
Only follow-up (no treatment) |
| ICER |
Dominant |